ClinicalTrials.gg
CompletedNCT01448239Updated Jun 28, 2013

Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)

A Phase 1 interventional study of alirocumab SAR236553 (REGN727) and alirocumab SAR236553 (REGN727) in Hypercholesterolemia, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-28.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
37th of 43
24 · median 107
Started
2011
with 6 others
Phase 1
9 of 43
none open now
Registered
7th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 37th largest by enrollment, is one of 7 that started in 2011, is one of 9 in phase 1, and was the 7th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

Injection Site Tolerability

Secondary Objectives:

  • To assess the safety profile of alirocumab SAR236553 (REGN727)
  • To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
Read the detailed description

The total duration of study for each subject is up to 15 weeks including a screening period up to 3 weeks.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Serum troponin I level should not exceed the upper laboratory limit of normal.
  • Male or female subject, between 18 and 65 years inclusive.
  • Body weight between 50.0 and 95.0 kg inclusive if male, between 40.0 kg and 85.0 kg inclusive if female, (BMI) between 18.0 and 30.0 kg/m² inclusive.
  • Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
  • Normal vital signs after 10 minutes resting in supine position.
  • Normal standard 12-lead after 10 minutes resting in supine position.
  • Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects
  • If female, subject must use a double method, except if she is sterilized for more than 3 months or .
  • Serum LDL-C levels>100 mg/dL at screening visit.

Exclusion criteria

Exclusion criteria:

  • Subjects indicated for the use of statins according to criteria in National Cholesterol Education Program adult treatment panel III Guidelines, as updated in 2004 (see Appendix C).
  • Initiation of a new diet or major change to a previous diet within 4 weeks prior to Screening (Day -21 to -2). Subjects must be willing to maintain a consistent diet for the duration of the study.
  • Use of a medication or nutraceutical in order to alter serum lipids within 4 weeks prior to screening (Day -21 to -2), including but not limited to statins, ezetimibe, fibrates, niacin, or omega-3 fatty acids, bile acid resins.
  • Fasting serum triglycerides >200 mg/dL measured after an 8 to 12 hour fast.
  • History of a reaction to doxycycline or similar compound.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    alirocumab SAR236553 (REGN727) - Dose A

    A single subcutaneous injection of Dose A

    Drug: alirocumab SAR236553 (REGN727)

  • Experimental
    alirocumab SAR236553 (REGN727) - Dose B

    A single subcutaneous injection of Dose B

    Drug: alirocumab SAR236553 (REGN727)

Interventions

06

What researchers measure

Primary outcomes

  1. Pain using present pain intensity (PPI) verbal questionnaire

    Time frame: 6 weeks

  2. Erythema at injection site by measuring diameter and qualitative assessment

    Time frame: 6 weeks

  3. Edema at injection site by measuring diameter and qualitative assessment

    Time frame: 6 weeks

Secondary outcomes

  1. Assessment of PK parameter - time to maximum concentration (tmax)

    Time frame: Up to 12 weeks

  2. Assessment of PK parameter - maximum concentration (Cmax)

    Time frame: Up to 12 weeks

  3. Assessment of PK parameter - area under curve (AUC)

    Time frame: Up to 12 weeks

  4. Assessment of PK parameter - cluster of differentiation (CD) biomarker (CD29)

    Time frame: Up to 12 weeks

  5. Assessment of PK parameter - terminal elimination half-life (t1/2z)

    Time frame: Up to 12 weeks

  6. Pharmacodynamics: Change in LDL-C from baseline

    Time frame: Up to 12 weeks

  7. Number of participants with Adverse Events

    Time frame: Up to 12 weeks

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2011
First posted
Oct 7, 2011
Start
Feb 2011
Primary completionActual
May 2011
CompletionActual
May 2011
Last update
Jun 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01448239
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 7, 2011
Start date
Feb 2011
Primary completion
May 2011
Completion
May 2011
Last update
Jun 28, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion